Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Edesa Biotech, Inc. (EDSA) was the subject of a Schedule 13G reporting shared beneficial ownership by StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross. Each may be deemed to beneficially own the same 1,407,181 Common Shares, comprising 825,000 Common Shares and 582,181 shares through exercise of pre-funded warrants; this is not a combined total across the three reporting persons. The reported 9.9% was rounded down. Its calculation used 13,503,723 Common Shares believed outstanding, as disclosed in the issuer’s Prospectus Supplement filed August 20, 2026, plus 582,181 warrant shares. A 9.99% beneficial ownership limitation applies; the calculation excludes 242,819 additional shares underlying the warrants.
Key Figures
Beneficial ownership amount:1,407,181 sharesCommon Shares held:825,000 sharesShares through pre-funded warrants:582,181 shares+4 more
7 metrics
Beneficial ownership amount1,407,181 sharesEach reporting person may be deemed to beneficially own this amount; the reported amount comprises Common Shares and shares through exercise of pre-funded warrants.
Common Shares held825,000 sharesComponent of the amount each reporting person may be deemed to beneficially own.
Shares through pre-funded warrants582,181 sharesIncluded in the beneficial ownership amount and in the percentage calculation.
Beneficial ownership limitation9.99%Limitation applicable to the pre-funded warrants.
Common Shares believed outstanding13,503,723 sharesAmount cited from the issuer’s Prospectus Supplement filed August 20, 2026; 582,181 warrant shares were added for the reported percentage calculation.
Excluded shares underlying warrants242,819 sharesShares underlying the pre-funded warrants excluded from the percentage calculation due to the beneficial ownership limitation.
"subject to a beneficial ownership limitation of 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Pre-Funded Warrantsfinancial
"582,181 shares of Common Shares through the exercise of the Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shared voting powerregulatory
"Shared voting power: 1,407,181"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared dispositive power: 1,407,181"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Edesa Biotech shares do StemPoint and Michelle Ross report?
StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross each may be deemed to beneficially own 1,407,181 Edesa Biotech Common Shares. That amount consists of 825,000 Common Shares and 582,181 shares through exercise of pre-funded warrants; it is the same reported position for each, not an aggregate across them.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Edesa Biotech, Inc.
(Name of Issuer)
Common Shares, without par value
(Title of Class of Securities)
27966L306
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
27966L306
1
Names of Reporting Persons
StemPoint Capital LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,407,181.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,407,181.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,407,181.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
27966L306
1
Names of Reporting Persons
StemPoint Capital Management GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,407,181.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,407,181.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,407,181.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.
SCHEDULE 13G
CUSIP Number(s):
27966L306
1
Names of Reporting Persons
Michelle Ross
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,407,181.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,407,181.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,407,181.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Edesa Biotech, Inc.
(b)
Address of issuer's principal executive offices:
100 Spy Court, Markham, Ontario, Canada L3R 5H6
Item 2.
(a)
Name of person filing:
This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").
(b)
Address or principal business office or, if none, residence:
The business addresses of each Reporting Person is:
520 Madison Avenue, 19th Floor
New York, NY 10022
(c)
Citizenship:
StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware.
StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware.
Michelle Ross is a citizen of the United States of America.
(d)
Title of class of securities:
Common Shares, without par value
(e)
CUSIP Number(s):
27966L306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 1,407,181 shares of Common Shares, without par value (the "Common Shares"), consisting of consisting of (i) 825,000 shares of Common Shares and (ii) 582,181 shares of Common Shares through the exercise of a pre-funded warrant (the "Pre-Funded Warrants"). The Pre-Funded Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation").
(b)
Percent of class:
Each Reporting Person may be deemed to beneficially own 9.9% shares of Common Shares, which is calculated based on (i) 13,503,723 Common Shares believed to be outstanding as disclosed in the Issuer's Prospectus Supplement on Form 424B5 filed with the Securities and Exchange Commission on August 20, 2026, plus 582,181 shares of Common Shares which may be acquired upon the exercise of the Pre-Funded Warrants, which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. The foregoing excludes 242,819 shares of Common Shares underlying the Pre-Funded Warrants, which is subject to the Beneficial Ownership Limitation. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
-0-
(ii) Shared power to vote or to direct the vote:
1,407,181. Comment: Shared voting power includes 582,181 Pre-Funded Warrants beneficially owned by the Reporting Persons.
(iii) Sole power to dispose or to direct the disposition of:
-0-
(iv) Shared power to dispose or to direct the disposition of:
1,407,181. Comment: Shared dispositive power includes 582,181 Pre-Funded Warrants beneficially owned by the Reporting Persons.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.